MediLink Therapeutics today announced that the first patient has been dosed with its Antibody Drug Conjugate (ADC) product YL201 in the United States. This is a multi-center nonrandomized, open-label, first-in-human phase I study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YL201 in patients with advanced solid tumors.
About MediLink Therapeutics
MediLink Therapeutics is a new concept antibody drug conjugate company and has built a differentiated proprietary Tumor Microenviroment Activable LINker (TMALIN) ADC technology platform. It generates homogeneous DAR8 ADC products with potential to resolve drug resistance issues of current ADC products. Headquartered in Suzhou, China and established R&D centers in Shanghai and Cambridge. MediLink Therapeutics focuses its clinical drug development on unmet medical needs and plans to further expand into new disease areas to serve global patients.
